TXA Central
TXA Central is a resource for health professionals caring for patients with acute severe bleeding
Category: Uncategorized
‘HER LIFE MATTERS’ DOCUMENTARY IS LIVE
This documentary ‘Her Life Matters’ asks why each year, world-wide tens of thousands of mothers bleed to death needlessly – lives that could be saved by a single injection of an inexpensive generic drug called tranexamic acid. Tranexamic acid was invented sixty years ago to stop mothers from bleeding to death after childbirth. The Woman trial showed that timely treatment
Details
WOMAN-2 Trial
The WOMAN-2 trial investigates Tranexamic Acid (TXA) for the prevention of postpartum bleeding in women with anaemia: an international, randomised, double-blind, placebo-controlled trial.
Details
Art for Maternal Health Awareness
Healthcare is a human-right. Sculpture artist, Moira Purver was commissioned by the WOMAN trial to create this spectacular bronze statue, appropriately titled WOMAN, that depicts a mother on her knees holding her new baby in her arms just after giving birth. Every year 14 million mothers develop severe bleeding after childbirth or postpartum haemorrhage (PPH)
Details
A CRASH-3 Trial Sub-Study Provides Evidence of TXA Benefit in TBI
This sub-study found that when patients with unreactive pupils at baseline were excluded, there was evidence that TXA prevents new haemorrhage (adjusted RR=0.80, 95% CI 0.66 to 0.98).
Details
World Day of Remembrance for Road Traffic Victims
Even though evidence on the benefits of TXA in trauma has been available for over a decade, most trauma victims are still not being treated with TXA soon enough, if at all.
Details
WOMAN-PharmacoTXA Trial
The WOMAN-PharmacoTXA trial is a randomised controlled trial to assess the pharmacokinetics and pharmacodynamics of intramuscular, intravenous, and oral administration of tranexamic acid in women giving birth by caesarean section
Details
World Health Organization reacts to the WOMAN Trial results
In response to the release of the WOMAN trial results, the World Health Organisation (WHO) department of reproductive health and research is working with the Cochrane Pregnancy and Childbirth group to fast-track the update of the existing Cochrane systematic review on the treatment of primary postpartum hemorrhage (PPH) with priority given to the use of
Details
Trauma-INTACT Results
The Trauma Intact trial: a clinical trial investigating pharmacokinetics of intramuscular tranexamic acid (TXA) in bleeding trauma patients TXA a drug that prevents severe bleeding after injury by inhibiting blood clot breakdown, is most effective when given soon after injury. Every 15 minutes treatment delay reduces its lifesaving potential by 10%. However, currently only 3%
Details
Nigerian Health Minister To Support the WOMAN-trial
Nigeria’s health minister, Professor Isaac Adewale has said that deaths of women due to postpartum haemorrhage (PPH), a severe form of bleeding after childbirth, was a huge problem in Nigeria and that he will promote the use of tranexamic acid to reduce these deaths. “This drug is not new in Nigeria, but now we want
Details